Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors | ||
| By: PR Newswire Association LLC. - 20 Sep 2017 | Back to overview list |
|
MADRID, September 20, 2017 /PRNewswire/ -- With the motivation of finding a solution to the unmet needs of patients with different types of cancer, PharmaMar (MCE: PHM) announces the start of a Phase I clinical study with PM14, a new antitumor compound resulting from the company´s internal investigation program for the treatment of patients with advanced solid tumors. (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b ) After its preclinical phase, where the compound has demonstrated its activity in solid tumors in animal models, this Phase I clinical study has the primary objective of identifying the optimal dose for the administration of PM14 in patients with advanced solid tumors. Secondary objectives of this trial are to assess the safety profile and to evaluate PM14´s pharmacokinetics and pharmacogenomics in this group of patients. The Director of Clinical Development at PharmaMar´s oncology business unit, Dr. Arturo Soto, underlined the commitment of PharmaMar in oncological investigation through its important pipeline of products in preclinical investigation along with a strong R&D program: "The start-up of this first clinical study in humans with PM14 continues our commitment to find new agents with novel mechanisms of action in the fight against cancer. We are very encouraged with the beginning of this trial as it puts us a little closer to our objective, improving the quantity and quality of life of cancer patients." The participation of approximately 50 patients with a confirmed diagnosis in advanced solid tumors, for which an available standard treatment doesn´t exist, is forecasted. Contact details: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500) 
|
||
|
|
||
 | Back to overview list | |